Listen to Episode 19 of BioVentureVoiCes video podcast w/ the legendary Christoph Westphal of Longwood Fund and hear about his long career in company creation and venture investing that has led to 20+ FDA Approved products and his history and connection w/ many biotech luminaries! The

Thanks to Wilson Sonsini’s Jen Fang and Michael Hostetler and the NextGen VC podcast for the thoughtful questions and engaging discussion on critical factors for success in entrepreneurship, early-stage VC financing and best practices for driving drug development success!

On today’s #BiotechHangout, Chris Garabedian, josh schimmer (Josh Schimmer), Nina Kjellson, Michael Yee (Mike Yee) & Tim Opler discuss Bruce Booth’s ‘Wisdom of Crowds’ blog post, Endpoints News 100 biotech survey, $ITOS shut down & wave of wind downs vs reverse mergers, latest developments at

Our next guest (Ep.20) on BioVenture VoiCes will be lindy fishburne, co-founder and Managing Partner of Breakout Ventures. She describes her early experiences at the dawn of the tech / genomics revolution and helping bridge the gap between a good life sciences startup ideas to an

Listen to Episode 20 of BioVentureVoiCes video podcast w/ lindy fishburne of Breakout Ventures and hear about her journey from the late 90s tech/genomics bubble to seeing the convergence o tech and life sciences and establishing Breakout Labs with The Thiel Foundation to establishment

on where this fda is headed - this will probably be my last post on the big bull bear debate of what direction is this fda going to take because i think it's clear at this point that fda is 1) not materially disrupted, 2) continues to be supportive of regulatory flexibility, and

our next guest (Ep.21) on BioVenture VoiCes will be Aaron Kantoff, Co-Founder and Managing Partner at Scion Life Sciences. He describes his initial interest in life sciences from his early investment/banking experience and his solid track record at Apple Tree Partners with Sam

Listen to Episode 21 of BioVentureVoiCes video podcast w/ Aaron Kantoff of Scion Life Sciences and hear about his early influences to pursue biotech VC and his successful partnership with his Scion co-founder Sam Hall at Apple Tree Partners. Aaron has been involved in a number

Powerful op-ed piece and an important voice in STAT⁩ on ⁦Sarepta Therapeutics⁩ gene therapy deaths from ⁦Christine McSherry⁩ DMD parent/advocate! $SRPT statnews.com/2025/06/18/sar…

Our next guest (Ep.22) on BioVenture VoiCes will be Glenn Rockman, Managing Partner at Adjuvant Capital Adjuvant Capital. He shares Adjuvant's focus on global health, impact investing and why the fund's strategy can address neglected areas of investment while also generating favorable

On today's #BiotechHangout Chris Garabedian, Daphne Zohar, Sam Fazeli, Paul Matteis, Tess Cameron & Tim Opler discuss market sentiment, #BIO2025 recap & BIO’s top priorities, FDA listening tour & Makary's potential role in $KALV’s rejection request, ACIP meeting recap, new CDER

Listen to Episode 22 of BioVentureVoiCes video podcast w/ Glenn Rockman of Adjuvant Capital and hear about Adjuvant's focus on global health, neglected and infectious disease investing and the case for generating returns for shareholders with a venture philanthropy and impact investing

𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: Chris Garabedian asked Adjuvant Capital's GLΞNN ROCKMAN 😑 what he thought of the news that the Gates Foundation will be accelerating the timeline to invest all of its money. See the full interview: biotechtv.com/post/bioventur…

Due to a late cancellation, we had to reschedule next week's BioVentureVoiCes episode, but we'll be back with Episode 23 on July 28th! Use this opportunity to catch up on past episodes on BiotechTV in the link below (also on Spotify and Apple Podcasts). Thanks to the thousands

On Today’s #BiotechHangout josh schimmer (Josh Schimmer), Chris Garabedian, Sam Fazeli, Yaron Werber & guest Adam Feuerstein ✡️ cover the latest at $SRPT (layoffs, black box, pipeline reprioritization), Makary & FDA: agency morale, rapid review for favorable drug pricing, CRL’s like $RARE

Our next guest (Ep.23) on BioVentureVoiCes will be Vineeta Agarwala Vineeta Agarwala, General Partner at a16z where she leads investments across biotech and healthcare. She shares the fund's overall strategy and the unique collaboration with Lilly on a separate $500mm venture fund,

Listen to Episode 23 of BioVentureVoiCes video podcast w/ Vineeta Agarwala (Vineeta Agarwala) of a16z and hear about the unique fund with Lilly and how the firm is viewing their investment strategy across heatlhcare. Vineeta shares how her early influences and experiences as an

𝐅𝐫𝐨𝐦 𝐘𝐞𝐬𝐭𝐞𝐫𝐝𝐚𝐲: Vineeta Agarwala describes to Chris Garabedian what she believes separates a16z from other VCs in early stage investing. See the full interview: biotechtv.com/post/bioventur…

Our next guest (Ep.24) on BioVentureVoiCes will be Srini Akkaraju, Founder and Managing General Partner at Samsara BioCapital (Samsara BioCapital) where he leads a multi-stage investment strategy from launching companies as first investor to PIPEs. Srini describes how his early

Listen to Episode 24 of BioVentureVoiCes video podcast w/ Srini Akkaraju of Samsara BioCapital and hear how his early involvement with SeaGen shaped his view on balancing opportunism with a long-term view on value creation. The full video is here on BiotechTV (and also on Spotify